Medicaid expansion gathers signatures in efforts to drive change
The proposed expansion aims to provide coverage to people who earn at or below 138 percent of the national poverty line. As of Friday, nearly 63,000 signatures have been collected, but over 880,000 signatures are still needed to qualify for the ballot.
The effort to expand Medicaid aims to increase healthcare access for low-income individuals by covering those at or below 138% of the poverty line, addressing current system gaps. While nearly 63,000 signatures have been collected, the campaign needs over 880,000 for the ballot.
It involves mobilizing volunteers and community engagement to promote Medicaid expansion.
If successful, the Medicaid expansion could greatly improve healthcare access for thousands of residents, offering vital coverage to those who need it most. Lawmakers keep pushing ahead with the signature collection effort, aiming to reach the necessary threshold for ballot inclusion.
Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Journals
28 minutes ago
- Business Journals
Medicaid cut reversal bill submitted by Hawley, who voted for them just days ago
Republican U.S. Sen. Josh Hawley from Missouri has submitted a bill that would reverse the Medicaid cuts made by President Donald Trump's "Big Beautiful Bill." Hawley submitted the bill just under two weeks after voting for the health care cuts. Hawley's proposed "Protect Medicaid and Rural Hospitals Act" repeals the changes that Trump's bill, which was signed into law on July 4, made to both Medicaid state-directed payments and taxes states could impose on healthcare providers. It also doubles the federal Rural Health Transformation Program's funding to $10 billion starting in 2031. "Now is the time to prevent any future cuts to Medicaid from going into effect,' Hawley said in a press release. 'We should also increase our support for rural hospitals around the country. Under the recent reconciliation bill, Missouri will see an extra $1 billion for hospitals over the next four years. I want to see Medicaid reductions stopped and rural hospitals fully funded permanently.' GET TO KNOW YOUR CITY Find Local Events Near You Connect with a community of local professionals. Explore All Events Hawley wrote up an opinion piece in the New York Times in May titled "Don't Cut Medicaid," in which he called cuts to the federal healthcare system "morally wrong." He then voted for the bill that made those cuts mandatory. He recently defended his flip-flop on the issue of Medicaid cuts, saying he voted for the bill because the legislation made it so that Missouri's rural hospitals are going to get $1 billion in funding over the next four years. But health policy expert Emily Gee, who used to work as an economist at the U.S. Department of Health and Human Services, told KSDK, "That's plainly not true." She said each state will actually have to apply and meet strict criteria to qualify for those competitive nationwide funds. "There's no guarantee that that will be the slice of the pie that Missouri gets," Gee said. View KSDK's full report here.
Yahoo
2 hours ago
- Yahoo
Many US employers plan to pare health benefits as weight-loss spending soars
By Amina Niasse NEW YORK (Reuters) -More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by consulting firm Mercer on Wednesday. Among employers with 500 or more workers, 51% said they planned to increase cost-sharing in 2026, including raising deductibles and maximum out-of-pocket costs for workers. That is up from 45% of large employers who said they would increase cost-sharing for 2025. Concern over the cost of GLP-1 weight-loss drugs like Novo Nordisk's Wegovy has surged, with 77% of employers naming them a top issue, the consultancy said. "More clients are saying ... 'I don't know how much longer we can sustain covering these medications'," said Alysha Fluno, a pharmacy innovation leader at Mercer, in an interview. While some employers have covered GLP-1s hoping for long-term health savings, rising prices are forcing a rethink: "Some employers facing big cost increases in 2026 may feel this coverage is out of reach," Fluno said. Greater competition in the weight-loss drug market in coming years will give pharmacy benefit managers more negotiating power with drugmakers and drive meaningful cost reductions, said Fluno. Novo's Wegovy and Eli Lilly's Zepbound are listed at $1086 and $1059, respectively, but many patients pay less through their health plans. Prescription drug costs jumped 8% last year, according to the survey. Mercer has forecast a 5.8% rise in overall health benefit costs for 2025. Employers are also eyeing alternatives to traditional pharmacy benefit managers (PBMs), according to Mercer. PBMs such as CVS Caremark, Cigna's Express Scripts and UnitedHealthcare's Optum Rx act as middlemen between drug companies and consumers. They negotiate volume discounts and fees with drug manufacturers on behalf of employers and health plans, create lists of medications that are covered by insurance, and reimburse pharmacies for prescriptions. Drugmakers say they take an undisclosed cut of the discounts they receive rather than sharing them with patients and payers. Regulatory scrutiny and calls for transparency are fueling interest in new models and emerging PBMs, with 34% of employers considering a switch. The survey found 40% of employers are considering alternative contracting models for their prescription medicine benefits, such as those that price drugs based on the wholesale price that retail pharmacies pay for them. Regulators have criticized the three largest pharmacy benefit managers for steering patients toward more expensive drugs and inflating prices to generate revenue gains, an accusation that the industry denies. California pension fund CalPERS, the second-largest public purchaser of health benefits in the U.S., announced on Tuesday that Caremark would replace UnitedHealth's Optum Rx as the fund's PBM in 2026. CalPERS said its five-year contract with Caremark requires the PBM to boost transparency and oversight.
Yahoo
2 hours ago
- Yahoo
These 2 Momentum Stocks Got a Bullish Nod — Here's Why They Could Reach New Highs
Buying into rising stocks is a natural impulse – and it's a viable investing strategy. Momentum investing, as it's called, is the art of finding and following the market's upward trends. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Of course, every investing style has its boosters and its bummers, and both sides usually have strong arguments in their favor. The key to success is finding balance, and remembering that while past performance won't guarantee a future return, it can still provide useful indications of where a stock is heading. With that in mind, let's dive into a pair of momentum stocks that are currently catching investors' attention. Using the TipRanks database, we've zeroed in on two names that have not only gained steam lately, but have also received bullish endorsements from at least one Street analyst. Let's take a look. BridgeBio Pharma (BBIO) The first momentum stock on our list today is BridgeBio, a biopharmaceutical company with a focus on genetic diseases that are both rare and serious. More specifically, BridgeBio has chosen disease targets with what it describes as 'clear genetic drivers'; that is, it is developing drug candidates to treat diseases that are genetically linked to single mutations. BridgeBio has chosen a rich field in which to work, as it can choose from more than 10,000 genetic diseases that meet its target criteria – and they impact tens of millions of patients globally. More importantly, this group of diseases has relatively few FDA-approved medications, giving BridgeBio plenty of openings. BridgeBio bases its development work on its proprietary drug development platform, looking for novel genetic diseases to target and then creating new medicines to address symptoms and improve patient outcomes. The company follows this development stage by moving a drug candidate from a successful clinical trial series and into the regulatory process, with commercialization being the final goal. BridgeBio reached that goal late last year. This past November, the company received FDA approval of its drug acoramidis for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), a disease that affects the heart muscle. Treatment with acoramidis was shown in clinical trials to reduce death and hospitalization from the disease, with statistically significant improvements in patients under treatment. BridgeBio is marketing the new drug under the brand name Attruby, and 1Q25 was the company's first full quarter of commercialization efforts. The company is still investigating acoramidis in the clinical trial program, where it is the subject of the Phase 3 ACT-EARLY study, testing whether the drug is useful in preventing asymptomatic patients who carry the pathogenic TTR variant from developing the active disease. Turning to the company's financial side, we find that BridgeBio's 1Q25 earnings release showed $116.6 million in total revenues, of which $36.7 million was net product revenue derived from sales of Attruby in the US following the drug's commercial launch. The balance of the company's revenue came from license and services income. Compared to the prior-year quarter, this segment of the revenue was down by $131.2 million, leading to the total revenue year-over-year decline of 45%, although the total haul actually beat Street expectations by $58 million, aided by Atturby's better-than-expected debut. BridgeBio ran a net loss in 1Q25, of 88 cents per share, yet this was 5 cents per share better than had been expected. Investors have liked the story here and the stock shows a strong gain for the year-to-date, up ~74%. BridgeBio has caught the attention of Oppenheimer analyst Trevor Allred, who is taking a more bullish stance on the shares in light of Attruby's successful commercialization. Allred writes, 'We've been wrong on BBIO since our initiation—Bridgebio's team has executed Attruby's launch superbly, and shares have been supported by commercial outperformance and a look-ahead to clinical catalysts at YE. Our trepidation around 2029 generic entry has not mattered for 2025 stock performance. We expect share outperformance to continue as 2025 Attruby sales clear consensus estimates, and we expect commercial success to be compounded by positive clinical results from ADH1 and LGMD2i clinical trials around YE. Our concerns regarding long-term revenue durability remain, but BBIO has time to demonstrate real-world datasets demonstrating benefit over tafamidis should generics become available in 2029.' Allred follows these comments with an upgrade from Perform (i.e., Neutral) to Outperform (i.e., Buy) rating for BBIO, and a $60 price target that implies a one-year upside potential of 26%. (To watch Allred's track record, click here) Overall, this stock has earned a Strong Buy consensus rating from the Street, based on 18 recent reviews that have a lopsided breakdown of 17 Buys to 1 Hold. The shares are priced at $47.69, and their $62.75 average target price suggests that the stock will gain 31.5% by this time next year. (See BBIO stock forecast) So-Young International (SY) Next up on our list of momentum stocks is So-Young, a Chinese company. The firm that operates a social media platform, linked to the medical aesthetics industry, and connecting the varied consumers, professionals, and medical service providers in the aesthetics sector. The platform makes available reliable and trustworthy information on a carefully vetted and curated network of medical aesthetic providers. The service platform focuses on content distribution in China, making use of major social media networks and other targeted media platforms. Social media and medical aesthetics are both growth industries, and So-Young is building a brand image based on user trust, an extensive reach, and valuable data insights. So-Young's user base can trade information on clinics, the latest treatment trends in aesthetics, and the quality of treatment, all permitting better patient decisions – and based on the trust engendered by sharing personal experiences. The company is working to expand its network, to add additional medical fields such as dentistry, dermatology, ophthalmology, and basic physical exams. The service is focused on China, and the company is based in Beijing. In its financial release for 1Q25, So-Young reported important gains in the number of active users on its network and the number of verified paid visits. The active users – defined as those who had visited an aesthetic clinic at least once in the previous 12 months – totaled more than 75,500, a massive gain from the 8,000 reported in the prior-year period. The gain in verified paid visits was similar, with 45,500 in 1Q25 compared to 4,600 in 1Q24. The company reported Q1 revenue at the high end of its previously published guidance range, with a top line of RMB297.3 million (approximately US$41 million) compared with RMB318.3 million in the first quarter of 2024, a figure that beat Street expectations by $0.8 million. The shares have been on a huge runup, up 411% this year, the bulk of the gains generated over the past month and this Chinese momentum stock has come to the attention of Citi analyst Nelson Cheung, who is impressed by the company's recent growth. Cheung says of So-Young and its prospects, 'Since launch in Nov 2024, SoYoung Clinic has quickly expanded with 31 centers in major cities (Beijing, Shanghai, Shenzhen) by end-Jun, verifying SY's strength in 1) differentiating brand position for quality standardized service and value-for-money mindshare for mass public; 2) increasing pricing power over procurement as it scales up; 3) effective online private domain cross-selling for accurate targeting and site selection; 4) proven execution for profitable store management with ~80% aesthetic centers generating +ve op cash flow in 1Q. We see meaningful catalysts to drive stock price further if: 1) improving monthly sales for flagship stores in Jun (e.g. Beijing Baoli); 2) potential exploration of full managed franchising model by end 2025; 3) solid exclusive product pipeline until 2027E.' (To watch Cheung's track record, click here) Looking forward, Cheung rates this stock as a Buy, with a $5.50 price target that suggests a one-year gain for the stock of 30%. Cheung's is the only analyst review on file for this stock, which is currently trading for $4.24. (See SY stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
